Third Compound from AMRI Bristol-Myers Squibb Collaboration Chosen for Preclinical Development

Third Compound from AMRI Bristol-Myers Squibb Collaboration Chosen for Preclinical Development
Trading Markets - 23 minutes ago
Nov 09, 2009 (Close-Up Media via COMTEX) -- BMY -- AMRI announced that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company will proceed into ...